Across TCGA pan-cancer cohorts, IL1RAPL2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IL1RAPL2 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IL1RAPL2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated IL1RAPL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, OV, and SCLC are the cancer types where IL1RAPL2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.